• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience
  • A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjuntive AZD6765 in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants

Disease
depressive disorder
Drug Name
AZD6765
Generic Name
AZD6765
Sponsor
AstraZeneca
Drug Status
In Development
Phase
II
Start Date
Oct 31, 2008
Study Name
D6702C00009
Study Id
D6702C00009
ClinicalTrials.gov ID
NCT00781742
Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013